NCT05084963

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Revolo Biotherapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
DRUG	IRL201104	lyophilised powder for reconstitution for IV dosing
DRUG	Placebo	Matching placebo for IRL201104

Timeline

• Start date: 2021-10-29
• Primary completion: 2022-10-24
• Completion: 2022-10-24
• First posted: 2021-10-20
• Last updated: 2025-05-21
• Results posted: 2025-05-21

Locations

23 sites across 1 country: United States

Regulatory

• FDA-regulated drug study